by @snowfloe.bsky.social
A feed about Multiple Sclerosis. Picks up these terms: #MSers #pwMS Multiple Sclerosis #MultipleSclerosis #MSchat #Neurological #MS #MSFriday #WeHaveMS #MSWeekend To avoid picking up too many irrelevant terms, the feed is CASE SENSITIVE., eg ms won't work. Write terms as they are above. WIP
Wheelie Out There Brittany C is passionate about Ballet Folklorico dancing, and got dxed with MS. "My immediate concern was, 'Will I still be able to dance?'… But the doctor [brought] hope: 'Once you get on a treatment, I would have no doubt that you will return to the stage.'” 1/2 #MultipleSclerosis #disability
Jacquie Sears Come see her unique self-expression ScribThought technique that helped to heal, soothe her mind, and comfort her anxiety one funky colorful line at a time. 🎨♿💗❤️🩹✍️ www.amazon.com/Not-just-eve... #Bookbluesky #chronicdisease #selfexpression #art #MS #MultipleSclerosis #Peace #Empathy #FeelToHeal
Kevin Byrne Even during fundraising season, there are priorities. 22 miles, then fundraising… #NeverStopNeverQuitForThem #MultipleSclerosis #nationalmssociety #VeteranSuicidePrevention #VetsReachOut
Newsramp Quantum BioPharma (NASDAQ: QNTM) signs deal with Thermo Fisher to launch Phase 2 trial of Lucid-MS, a first-in-class neuroprotective therapy targeting progressive multiple sclerosis. FDA cleared the IND just two months ago. #MultipleSclerosis #Biopharma
Newsramp Quantum BioPharma (NASDAQ: QNTM) has signed a Study Start-Up Agreement with Thermo Fisher to launch its Phase 2 Lucid-MS trial. Unlike traditional MS drugs, Lucid-MS targets nerve demyelination rather than suppressing the immune system — a potentially game-changing approach. #MultipleSclerosis #Biop
Newsramp Quantum BioPharma (QNTM) signs a Study Start-Up Agreement with Thermo Fisher Scientific to launch a Phase 2 trial of Lucid-MS, a novel neuroprotective MS therapy targeting demyelination rather than immune suppression. #MultipleSclerosis #Biopharma
JAMA Neurology Among patients with relapsing #MultipleSclerosis, earlier and continuous ocrelizumab treatment was associated with better long-term relapse and disability control than delayed initiation after interferon beta-1a. ja.ma/3TOyWso
Kevin Byrne A surprise after October Garage Dayz: no pain! My response is to push, push, push #NeverStopNeverQuitForThem #MultipleSclerosis #MS #nationalmssociety #CanYouTRK
Kevin Byrne Please donate to support our fight! NeverStopNeverQuit.com/donate #NeverStopNeverQuitForThem #MultipleSclerosis #MS #nationalmssociety #CanYouTRK
Newsramp Quantum BioPharma (NASDAQ: QNTM) is developing Lucid-MS, a novel drug candidate targeting the enzyme behind myelin destruction in MS. With ~3 million people affected globally and no cure in sight, new approaches are urgently needed. #MultipleSclerosis #Biotech
Newsramp Quantum BioPharma (NASDAQ: QNTM) is developing Lucid-MS, targeting the enzyme behind myelin destruction in MS patients. With ~3 million people affected globally and no approved therapy reversing neurodegeneration, this candidate could fill a critical gap. #MultipleSclerosis #Biopharma
Newsramp Quantum BioPharma (NASDAQ: QNTM) is developing Lucid-MS, targeting the enzyme behind myelin destruction in MS patients. With ~3 million people affected globally and no approved therapy reversing neurodegeneration, this candidate could fill a critical gap. #MultipleSclerosis #Biopharma
Newsramp Quantum BioPharma (NASDAQ: QNTM) has received FDA approval to advance Lucid-MS into phase 2 clinical trials for multiple sclerosis. The drug showed a strong safety profile in phase 1 and uses a distinct mechanism from existing MS therapies. #Biopharma #MultipleSclerosis
Newsramp Quantum BioPharma (NASDAQ: QNTM) receives FDA approval to advance Lucid-MS into Phase 2 clinical trials for multiple sclerosis. The drug showed a strong safety profile in Phase 1 and features a proprietary mechanism that sets it apart from existing therapies. #Biopharma #MultipleSclerosis
Newsramp Quantum BioPharma (QNTM) signs a Study Start-Up Agreement with Thermo Fisher Scientific to launch a Phase 2 trial of Lucid-MS, its first-in-class neuroprotective treatment for progressive multiple sclerosis, following FDA clearance. #MultipleSclerosis #ClinicalTrials
Newsramp Quantum BioPharma (NASDAQ: QNTM) signs Study Start-Up Agreement with Thermo Fisher Scientific to advance its Phase 2 trial of Lucid-MS, a first-in-class neuroprotective treatment for progressive multiple sclerosis. #MultipleSclerosis #Biopharma
Newsramp Quantum BioPharma (NASDAQ: QNTM) is advancing Lucid-MS into Phase 2 trials for multiple sclerosis while its unbuzzd spinout delivers a 7% royalty stream up to $250M. A dual-track strategy targeting both pharma and wellness markets. #Biotech #MultipleSclerosis
Newsramp Quantum BioPharma (NASDAQ: QNTM) is advancing Lucid-MS into a Phase 2 MS trial while holding a 20% stake and 7% royalty stream in alcohol-metabolism product unbuzzd. A dual pipeline worth watching. #Biotech #MultipleSclerosis